PRAC issues new safety warning for diclofenac

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC), the key European body responsible for investigating safety concerns of member states, has issued new recommendations including safety warnings for widely used, anti-inflammatory drug diclofenac.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC), the key European body responsible for investigating safety concerns of member states, has issued new recommendations including safety warnings for widely used, anti-inflammatory drug diclofenac.

Following an investigation by the PRAC into cardiovascular risks associated with the use of pain relief medicine diclofenac, at the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category